Compare BioNTech SE - ADR (BNTX) vs Royal Caribbean Cruises Ltd (RCL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BioNTech SE - ADR vs Royal Caribbean Cruises Ltd — how do they compare? BioNTech SE - ADR trades at $92.99 (market cap $23.31B), while Royal Caribbean Cruises Ltd trades at $307.66 (market cap $82.15B). The key difference: Royal Caribbean Cruises Ltd is far larger — about 3.5× BioNTech SE - ADR's market cap, and Royal Caribbean Cruises Ltd pays a 1.63% dividend while BioNTech SE - ADR pays none. Which is the better fit depends on your goals.
| BNTX | RCL | |
|---|---|---|
Market Cap | $23.31B | $82.15B |
Sector | Health | Consumer Cyclical |
52-Week High | $119.34 | $365.84 |
52-Week Low | $83.89 | $246.71 |
Enterprise Value | $6.60B | $104.79B |
Dividend Yield | — | 1.63% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BioNTech (BNTX) trades at $92.80, down 0.93% on the day, reflecting ongoing pressure from declining COVID-19 vaccine revenue. The stock shows a bullish technical signal from moving averages but faces fundamental headwinds with a net loss of $1.14 billion in 2025 and negative profit margins. Recent Q2 2026 earnings missed expectations, and the company lowered its full-year sales outlook due to soft vaccine demand. Analyst consensus remains strongly bullish with a $121 price target, betting on the long-term potential of its oncology pipeline.
The investment case hinges on BioNTech's transition from COVID-19 vaccines to its deep oncology pipeline, valued near zero given its cash-rich balance sheet. Near-term risks include persistent earnings losses and volatile vaccine revenue, but the company's strong liquidity position and 14 pivotal clinical trials offer substantial upside if pipeline successes materialize. Investors are essentially getting the oncology assets for free, but execution risk is high.
Royal Caribbean (RCL) trades at $308, down 3.75% today, as strong earnings growth and bullish technical signals are tempered by geopolitical concerns affecting European demand. The company reported Q2 2026 EPS of $4.21, beating estimates, and raised full-year guidance, with revenue reaching $17.93B in 2025. Technical analysis shows a bullish trend with support at $305 and resistance at $314, while fundamentals highlight robust profitability with a 23.54% net margin and 45.33% ROE.
RCL presents a compelling growth story with record bookings and fleet expansion through 2028, though risks include high debt levels, capital-intensive spending, and geopolitical volatility. Analyst consensus is bullish with a $343 price target, but investors should weigh strong cash flow generation against ongoing investment requirements and market sensitivity to economic cycles.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About BioNTech SE - ADR
BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including COVID-19. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens, neoantigens, cytokines, and antibodies.
Read more on BNTX →About Royal Caribbean Cruises Ltd
Royal Caribbean is the world's second-largest cruise company, operating 64 ships across five global and partner brands in the cruise vacation industry, with 10 more ships on order. Brands the company operates include Royal Caribbean International, Celebrity Cruises, and Silversea. The company also has a 50% investment in a joint venture that operates TUI Cruises and Hapag-Lloyd Cruises, allowing it to compete on the basis of innovation, quality of ships and service, variety of itineraries, choice of destinations, and price. The company completed the divestiture of its Azamara brand in the first quarter of 2021.
Read more on RCL →
